Brief: Canbridge Pharmaceuticals Posts FY Loss Attributable RMB483.5 Million
31/03/2023 02:00
March 31 (Reuters) - Canbridge Pharmaceuticals Inc
1228.HK :
* FY LOSS ATTRIBUTABLE RMB483.5 MILLION VERSUS LOSS RMB1.08
BILLION
* FY REVENUE RMB79 MILLION VERSUS RMB31.2 MILLION
Source text for Eikon: ID:nHKS6lZD9G
Further company coverage: 1228.HK
((reuters.briefs@thomsonreuters.com;))
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares